|Ms. Rachel K. King||Pres, CEO & Director||834.9k||N/A||1959|
|Mr. Brian M. Hahn||Sr. VP, CFO & Sec.||524.45k||N/A||1974|
|Dr. John L. Magnani||Sr. VP of Research & Chief Scientific Officer||549.36k||N/A||1953|
|Dr. Helen M. Thackray||Sr. VP of Clinical Devel. & Chief Medical Officer||593.23k||N/A||1968|
|Mr. Henry Flanner||VP of Technical Operations||N/A||N/A||N/A|
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
GlycoMimetics, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.